Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic
In a hot market market for NASH, having big-name backers can help shine a spotlight on startup players looking to make a mark. That was certainly the case for Terns Pharmaceuticals and partner Eli Lilly, which provided seed funding and licensed three NASH candidates to the baby biotech back in 2018.
Now, with two of those candidates in the clinic, Terns has bagged new funding to help speed toward the finish line.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.